190 related articles for article (PubMed ID: 32412177)
1. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
[TBL] [Abstract][Full Text] [Related]
2. The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer.
Guo L; Chen B; Zhang G; Wang Y; Cao L; Ren C; Wen L; Lin J; Wei G; Liao N
Gene; 2020 Oct; 759():144970. PubMed ID: 32711101
[TBL] [Abstract][Full Text] [Related]
3. Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.
Lin X; Lin X; Guo L; Wang Y; Zhang G
Thorac Cancer; 2022 Dec; 13(24):3441-3450. PubMed ID: 36305094
[TBL] [Abstract][Full Text] [Related]
4. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
6. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
[TBL] [Abstract][Full Text] [Related]
7. Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Li K; Liao N; Chen B; Zhang G; Wang Y; Guo L; Wei G; Jia M; Wen L; Ren C; Cao L; Mok H; Li C; Lin J; Chen X; Zhang Z; Hou T; Li M; Liu J; Balch CM; Liao N
Breast Cancer Res Treat; 2020 Sep; 183(2):321-332. PubMed ID: 32638235
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
Silwal-Pandit L; Vollan HK; Chin SF; Rueda OM; McKinney S; Osako T; Quigley DA; Kristensen VN; Aparicio S; Børresen-Dale AL; Caldas C; Langerød A
Clin Cancer Res; 2014 Jul; 20(13):3569-80. PubMed ID: 24803582
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Fernández-Cuesta L; Oakman C; Falagan-Lotsch P; Smoth KS; Quinaux E; Buyse M; Dolci MS; Azambuja ED; Hainaut P; Dell'orto P; Larsimont D; Francis PA; Crown J; Piccart-Gebhart M; Viale G; Leo AD; Olivier M
Breast Cancer Res; 2012 May; 14(3):R70. PubMed ID: 22551440
[TBL] [Abstract][Full Text] [Related]
10. Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients.
Wen L; Zhang G; Ren C; Li X; Mok H; Jia M; Wang Y; Chen B; Li K; Cao L; Li C; Xiao W; Lai J; Lin J; Wei G; Li Y; Zhang Y; Chen X; Liao N
Cancer Manag Res; 2021; 13():3055-3065. PubMed ID: 33854375
[TBL] [Abstract][Full Text] [Related]
11. Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
Melhem-Bertrandt A; Bojadzieva J; Ready KJ; Obeid E; Liu DD; Gutierrez-Barrera AM; Litton JK; Olopade OI; Hortobagyi GN; Strong LC; Arun BK
Cancer; 2012 Feb; 118(4):908-13. PubMed ID: 21761402
[TBL] [Abstract][Full Text] [Related]
12. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
[TBL] [Abstract][Full Text] [Related]
13. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Liu B; Yi Z; Guan Y; Ouyang Q; Li C; Guan X; Lv D; Li L; Zhai J; Qian H; Xu B; Ma F; Zeng Y
Cancer Med; 2022 Jul; 11(14):2767-2778. PubMed ID: 35393784
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of cell cycle-related genes in HR+/HER2- breast cancer.
Lai J; Chen B; Li Y; Lin X; Li M; Liu J; Liao N
Breast Cancer; 2022 Jan; 29(1):121-130. PubMed ID: 34449047
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
[TBL] [Abstract][Full Text] [Related]
16. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer.
Boyle DP; McArt DG; Irwin G; Wilhelm-Benartzi CS; Lioe TF; Sebastian E; McQuaid S; Hamilton PW; James JA; Mullan PB; Catherwood MA; Harkin DP; Salto-Tellez M
Histopathology; 2014 Sep; 65(3):340-52. PubMed ID: 24612173
[TBL] [Abstract][Full Text] [Related]
18. TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays.
Lin CH; Chen IC; Huang CS; Hu FC; Kuo WH; Kuo KT; Wang CC; Wu PF; Chang DY; Wang MY; Chang CH; Chen WW; Lu YS; Cheng AL
Sci Rep; 2015 Dec; 5():17879. PubMed ID: 26671300
[TBL] [Abstract][Full Text] [Related]
19. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis markers in breast cancer--potentially useful tools for priority setting of anti-angiogenic agents.
Keyhani E; Muhammadnejad A; Behjati F; Sirati F; Khodadadi F; Karimlou M; Moghaddam FA; Pazhoomand R
Asian Pac J Cancer Prev; 2013; 14(12):7651-6. PubMed ID: 24460348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]